This study has been suspended.
(Temporarily suspended: waiting for Indian Governement clearance )
Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India
The primary study hypothesis is that a two-dose human papillomavirus (HPV) vaccine regimen would offer similar immunogenicity and protection as that of a three-dose regimen to girls against persistent HPV infection and cervical neoplasia caused by HPV types included in the vaccine.
View study details here.